Exploiting graft-versus-tumour responses using donor leukocyte infusions

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic stem cell transplantation (SCT) is a primary treatment for hematological malignancies, enabling higher chemotherapy doses.
• Dose escalation alone is often insufficient for complete eradication of malignancy.
• An immune-mediated graft-versus-malignancy (GVM) effect is increasingly recognized as vital for therapeutic success.

Purpose of the Study:

• To explore the significance of the graft-versus-malignancy effect in allogeneic stem cell transplantation.
• To review evidence supporting the GVM effect and its relationship with graft-versus-host-disease (GVHD).
• To identify unresolved questions regarding GVM, including effector cells, target antigens, and therapeutic strategies.

Main Methods:

• Review of existing literature and clinical observations.
• Analysis of patient data regarding relapse rates post-SCT.
• Evaluation of outcomes following donor lymphocyte infusions (DLI) for relapsed malignancies.

Main Results:

• Relapse remission after immunosuppression withdrawal suggests GVM activity.
• Lower relapse rates correlate with graft-versus-host-disease (GVHD) development.
• Increased relapse risk observed in syngeneic or T-cell depleted SCT indicates the importance of allogeneic immune interactions.
• Donor lymphocyte infusions show efficacy, particularly in chronic myeloid leukemia (CML).

Conclusions:

• The graft-versus-malignancy effect plays a critical role in eradicating hematological malignancies post-SCT.
• Further research is needed to elucidate effector cells, target antigens, and optimal strategies to harness GVM while minimizing GVHD.
• Investigating adjuvant therapies and non-myeloablative transplantation approaches is essential for refining SCT protocols.